{
  "nctId": "NCT04329702",
  "briefTitle": "Mobile Coping Skills Training to Improve Cardiorespiratory Failure Survivors' Psychological Distress",
  "officialTitle": "Optimizing a Self-directed Mobile Coping Skills Training Intervention to Improve Cardiorespiratory Failure Survivors' Psychological Distress",
  "protocolDocument": {
    "nctId": "NCT04329702",
    "filename": "Prot_001.pdf",
    "label": "Study Protocol",
    "date": "2020-07-22",
    "uploadDate": "2022-08-04T08:58",
    "size": 1002649,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT04329702/document/Prot_001.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "NA"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "RANDOMIZED",
  "interventionModel": "PARALLEL",
  "masking": "DOUBLE",
  "enrollmentInfo": {
    "enrollmentCount": 45,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2020-12-03",
    "completionDate": "2022-03-31",
    "primaryCompletionDate": "2021-12-31",
    "firstSubmitDate": "2020-03-30",
    "firstPostDate": "2020-04-01"
  },
  "eligibilityCriteria": {
    "criteria": "INCLUSION CRITERIA\n\n1. Adult (age ≥18)\n2. Managed in a hospital setting for ≥24 hours during the time inclusion criterion #3 is met.\n3. Acute cardiorespiratory failure / insufficiency, defined as ≥1 of the following:\n\n   * mechanical ventilation via endotracheal tube for ≥4 hours\n   * non-invasive ventilation (CPAP, BiPAP) for ≥4 hours in a 24-hour period provided for acute respiratory failure\n   * new use of supplemental oxygen ≥2 liters per minute (or increase in baseline continuous oxygen)\n   * use of vasopressors for shock of any etiology\n   * use of inotropes for shock of any etiology\n   * use of pulmonary vasodilators\n   * use of aortic balloon pump or cardiac assist device for cardiogenic shock\n   * use of diuretic intravenous drip\n4. Cognitive status intact\n\n   * No history of pre-existing significant cognitive impairment (e.g., dementia) as per medical chart\n   * Absence of current significant cognitive impairment (impairment defined as ≥3 errors on the Callahan cognitive status screen)\n   * Decisional capacity present\n5. Absence of severe and/or persistent mental illness\n\n   * Treatment for severe and/or persistent mental illness (e.g., psychosis, bipolar affective disorder, schizoaffective disorder, schizoid personality disorder, schizophrenia \\[as per medical record\\], hospitalization for any psychiatric disorder) within the 6 months preceding the current hospital admission\n   * No endorsement of active suicidality at time of admission or informed consent\n   * No active substance abuse at a severity that impairs ability to participate\n6. Functional English fluency\n\nEXCLUSION CRITERIA (in hospital):\n\n1. Complex medical care expected soon after discharge (e.g., planned surgeries, transplantation evaluation, extensive travel needs for follow up care, disruptive chemotherapy/radiation regimen)\n2. Unable to complete study procedures as determined by staff\n3. Lack of access to either reliable smartphone with cellular data plan or wifi\n\nINCLUSION CRITERIA (post-discharge)\n\n1\\. Elevated baseline (T1) psychological distress symptoms, defined as HADS total score of ≥8\n\nEXCLUSION CRITERIA (post-discharge)\n\n1. Failure to randomize within 2 months post-discharge.\n2. Failure to access app within 1 month after randomization in the absence of other explanation (e.g., hospitalization).",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Change in Hospital Anxiety and Depression Scale (HADS) Questionnaire",
        "description": "Depression and anxiety symptoms. Scores range from 0 (better) to 42 (worse)",
        "timeFrame": "Between baseline and 1 month post-randomization"
      }
    ],
    "secondary": [
      {
        "measure": "Change in Hospital Anxiety and Depression Scale (HADS) Questionnaire",
        "description": "Depression and anxiety symptoms. Scores range from 0 (better) to 42 (worse)",
        "timeFrame": "Between baseline and 3 months post-randomization"
      },
      {
        "measure": "Change in Post-Traumatic Stress Symptom Inventory (PTSS)",
        "description": "Post-traumatic stress disorder symptoms. Scores can range from 10 (best) to 70 (worst).",
        "timeFrame": "Between baseline and 1 month post-randomization"
      },
      {
        "measure": "Change in Post-Traumatic Stress Symptom Inventory (PTSS)",
        "description": "Post-traumatic stress disorder symptoms. Scores can range from 10 (best) to 70 (worst).",
        "timeFrame": "Between baseline and 3 months post-randomization"
      },
      {
        "measure": "Client Satisfaction Questionnaire (CSQ)",
        "description": "A measure of acceptability. Scores can range from 5 (worst) to 35 (best)",
        "timeFrame": "1 month post-randomization"
      },
      {
        "measure": "Intervention Adherence",
        "description": "Measured by how many total tasks of the 33 possible that participants completed within the app during the intervention. Note that a value \\>33 indicates that participants completed more tasks than required.",
        "timeFrame": "1 month post-randomization"
      },
      {
        "measure": "Change in Quality of Life Visual Analog Scale",
        "description": "A measure of quality of life. Scores can range from 0 (worst) to 100 (best)",
        "timeFrame": "Between baseline and 1 month post-randomization"
      },
      {
        "measure": "Change in Quality of Life Visual Analog Scale",
        "description": "A measure of quality of life. Scores can range from 0 (worst) to 100 (best)",
        "timeFrame": "Between baseline and 3 month post-randomization"
      },
      {
        "measure": "Patient Health Questionnaire 10-item Scale (PHQ-10)",
        "description": "An adapted version of the PHQ-15; a measure of physical symptoms. Scores can range from 0 (best) to 30 (worst).",
        "timeFrame": "1 month post-randomization"
      },
      {
        "measure": "Patient Health Questionnaire 10-item Scale (PHQ-10)",
        "description": "An adapted version of the PHQ-15; a measure of physical symptoms. Scores can range from 0 (best) to 30 (worst).",
        "timeFrame": "3 months post-randomization"
      },
      {
        "measure": "Distress Associated With Depression and Anxiety Symptom Frequency",
        "description": "A visual analog scale appended to the HADS which allows participants to report how distressing they perceive the depression and anxiety symptoms to be that they reported in the HADS. Scores range from 0 (best) to 100 (worst)",
        "timeFrame": "Between baseline and 1 month post-randomization"
      },
      {
        "measure": "Distress Associated With Depression and Anxiety Symptom Frequency",
        "description": "A visual analog scale appended to the HADS which allows participants to report how distressing they perceive the depression and anxiety symptoms to be that they reported in the HADS. Scores range from 0 (best) to 100 (worst)",
        "timeFrame": "Between baseline and 3 months post-randomization"
      },
      {
        "measure": "Distress Associated With PTSD Symptom Frequency",
        "description": "A visual analog scale appended to the PTSS which allows participants to report how distressing they perceive the depression and anxiety symptoms to be that they reported in the PTSS. Scores range from 0 (best) to 100 (worst)",
        "timeFrame": "Between baseline and 1 month post-randomization"
      },
      {
        "measure": "Distress Associated With PTSD Symptom Frequency",
        "description": "A visual analog scale appended to the PTSS which allows participants to report how distressing they perceive the depression and anxiety symptoms to be that they reported in the PTSS. Scores range from 0 (best) to 100 (worst)",
        "timeFrame": "Between baseline and 3 months post-randomization"
      }
    ],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 1,
      "secondaryCount": 13,
      "otherCount": 0,
      "totalCount": 14
    },
    "studyDesign": {
      "phases": [
        "NA"
      ],
      "isRandomized": true,
      "isMasked": true,
      "interventionModel": "PARALLEL"
    },
    "overallComplexityScore": 100,
    "complexityCategory": "Highly Complex"
  },
  "collectionDate": "2025-09-22T02:29:18.844Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}